Impact of the EU Paediatric Medicine Regulation on new anti-cancer medicines for the treatment of children and adolescents.

Vassal G, de Rojas T, Pearson ADJ

Open source

DOI
10.1016/s2352-4642(22)00344-3
Published
2023 Mar
Container
The Lancet. Child & adolescent health
Publisher
Not recorded
Open access
no

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1016/s2352-4642-22-00344-3,
  title = {Impact of the EU Paediatric Medicine Regulation on new anti-cancer medicines for the treatment of children and adolescents.},
  author = {Vassal G and de Rojas T and Pearson ADJ},
  year = {2023},
  journal = {The Lancet. Child \& adolescent health},
  doi = {10.1016/s2352-4642(22)00344-3},
  url = {https://doi.org/10.1016/s2352-4642(22)00344-3}
}

RIS

TY  - JOUR
TI  - Impact of the EU Paediatric Medicine Regulation on new anti-cancer medicines for the treatment of children and adolescents.
AU  - Vassal G
AU  - de Rojas T
AU  - Pearson ADJ
PY  - 2023
JO  - The Lancet. Child & adolescent health
DO  - 10.1016/s2352-4642(22)00344-3
UR  - https://doi.org/10.1016/s2352-4642(22)00344-3
ER  - 

APA

G, V., T, D. R., & ADJ, P. (2023). Impact of the EU Paediatric Medicine Regulation on new anti-cancer medicines for the treatment of children and adolescents.. The Lancet. Child & adolescent health. https://doi.org/10.1016/s2352-4642(22)00344-3

Source records